Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term
Disease control
Completed
This study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by review…
Sponsor: European EGPA Study Group • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC